数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Immune rejection is a major cause of graft dysfunction following organ transplantation, and CD4+ T cells play a critical role in this process.
方法
Esculetin is a natural coumarin compound derived from the Chinese herbal medicine Fraxinus.
核心结论
Although its anti-tumor and anti-inflammatory effects have been extensively investigated, its potential role in transplant immunology remains unexplored.；The effect of esculetin on transplant rejection and CD4+ T cells was evaluated by survival curve analysis, H&E staining, immunohistochemical staining, flow cytometry, and RNA sequencing.；The effects of esculetin on the phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT)-mechanistic target of rapamycin (mTOR) pathway, cell cycle, apoptosis, and glycolytic metabolism in CD4+ T cells were also examined.；The functional rescue experiments were performed by combining esculetin with the PI3K activator 740Y-P and inhibitor LY294002. ‖ 结论：The present study is the first to demonstrate that esculetin attenuates immune rejection in mouse skin and heart transplantation models by modulating the PI3K-AKT-mTOR signaling pathway in CD4+ T cells, thereby exerting inhibitory effects on proliferation, induction of apoptosis, and suppression of glycolytic metabolism.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★★☆☆ 炎症衰老是几乎所有慢性老年病的公共通路，也是最有希望做"抗炎但保留免疫"解耦的靶点。
原文题录
- 英文标题：Esculetin alleviates mouse transplant rejection by modulating CD4+ T cell functional responses and glycolytic metabolism via the PI3K-AKT-mTOR axis.
- 期刊与标识：Int Immunopharmacol · PMID 42945918 · DOI 10.1016/j.intimp.2026.117573**
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。